Cancer stem cell-targeted bio-imaging and chemotherapeutic perspective

Jiyou Han; Miae Won; Ji Hyeon Kim; Eugeine Jung; Kyungim Min; Paramesh Jangili; Jong Seung Kim

doi:10.1039/d0cs00379d

Cancer stem cell-targeted bio-imaging and chemotherapeutic perspective

Jiyou Han, Miae Won, Ji Hyeon Kim, Eugeine Jung, Kyungim Min, Paramesh Jangili, Jong Seung Kim

Research output: Contribution to journal › Review article › peer-review

89 Citations (Scopus)

Abstract

Cancer stem cells (CSCs), also called tumor-initiating cells (TICs), have been studied intensively due to their rapid proliferation, migration, and role in the recurrence of cancer. In general, CSC marker-positive cells [CD133, CD44, CD166, aldehyde dehydrogenase (ALDH), and epithelial cell adhesion molecule (EpCAM)] exhibit a 100-fold increased capacity to initiate cancer. Within a heterogeneous tumor mass, only approximately 0.05-3% of cells are suspected to be CSCs and able to proliferate under hypoxia. Interestingly, CSCs, cancer cells, and normal stem cells share many cytochemical properties, such as inhibition of the redox system for reactive oxygen species (ROS) production and high expression of drug resistance transporters. However, compared to normal stem cells, CSCs develop unique metabolic flexibility, which involves switching between oxidative phosphorylation (OXPHOS) and glycolysis as their main source of energy. Due to the similarities between CSCs and other cancer cells and normal stem cells, limited chemotherapeutic and bio-imaging reagents specific for CSCs have been developed. In this short review, we address the current knowledge regarding CSCs with a focus on designing chemotherapeutic and bio-imaging reagents that target CSCs.

Original language	English
Pages (from-to)	7856-7878
Number of pages	23
Journal	Chemical Society Reviews
Volume	49
Issue number	22
DOIs	https://doi.org/10.1039/d0cs00379d
Publication status	Published - 2020 Nov 21

Bibliographical note

Funding Information:
This work was supported by the CRI project (grant no. 2018R1A3B1052702 to J. S. K.), the Basic Science Research Programs (grant no. 2018R1A2B6002275 to J. H. and 2017R1D1A1B03030062 to M. W.) and the global PhD fellowship (GPF) program (2019H1A2A1074096, J. H. K.) of the National Research Foundation of Korea (NRF), funded by the Ministry of Education. We also gratefully acknowledge support from Korea University and Hyupsung University.

Publisher Copyright:
© The Royal Society of Chemistry.

ASJC Scopus subject areas

Chemistry(all)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1039/d0cs00379d

Cite this

@article{b1b9f44a2b70461b9d72df98bbbf6214,

title = "Cancer stem cell-targeted bio-imaging and chemotherapeutic perspective",

abstract = "Cancer stem cells (CSCs), also called tumor-initiating cells (TICs), have been studied intensively due to their rapid proliferation, migration, and role in the recurrence of cancer. In general, CSC marker-positive cells [CD133, CD44, CD166, aldehyde dehydrogenase (ALDH), and epithelial cell adhesion molecule (EpCAM)] exhibit a 100-fold increased capacity to initiate cancer. Within a heterogeneous tumor mass, only approximately 0.05-3% of cells are suspected to be CSCs and able to proliferate under hypoxia. Interestingly, CSCs, cancer cells, and normal stem cells share many cytochemical properties, such as inhibition of the redox system for reactive oxygen species (ROS) production and high expression of drug resistance transporters. However, compared to normal stem cells, CSCs develop unique metabolic flexibility, which involves switching between oxidative phosphorylation (OXPHOS) and glycolysis as their main source of energy. Due to the similarities between CSCs and other cancer cells and normal stem cells, limited chemotherapeutic and bio-imaging reagents specific for CSCs have been developed. In this short review, we address the current knowledge regarding CSCs with a focus on designing chemotherapeutic and bio-imaging reagents that target CSCs.",

author = "Jiyou Han and Miae Won and Kim, {Ji Hyeon} and Eugeine Jung and Kyungim Min and Paramesh Jangili and Kim, {Jong Seung}",

note = "Funding Information: This work was supported by the CRI project (grant no. 2018R1A3B1052702 to J. S. K.), the Basic Science Research Programs (grant no. 2018R1A2B6002275 to J. H. and 2017R1D1A1B03030062 to M. W.) and the global PhD fellowship (GPF) program (2019H1A2A1074096, J. H. K.) of the National Research Foundation of Korea (NRF), funded by the Ministry of Education. We also gratefully acknowledge support from Korea University and Hyupsung University. Publisher Copyright: {\textcopyright} The Royal Society of Chemistry.",

year = "2020",

month = nov,

day = "21",

doi = "10.1039/d0cs00379d",

language = "English",

volume = "49",

pages = "7856--7878",

journal = "Chemical Society Reviews",

issn = "0306-0012",

publisher = "Royal Society of Chemistry",

number = "22",

}

TY - JOUR

T1 - Cancer stem cell-targeted bio-imaging and chemotherapeutic perspective

AU - Han, Jiyou

AU - Won, Miae

AU - Kim, Ji Hyeon

AU - Jung, Eugeine

AU - Min, Kyungim

AU - Jangili, Paramesh

AU - Kim, Jong Seung

N1 - Funding Information: This work was supported by the CRI project (grant no. 2018R1A3B1052702 to J. S. K.), the Basic Science Research Programs (grant no. 2018R1A2B6002275 to J. H. and 2017R1D1A1B03030062 to M. W.) and the global PhD fellowship (GPF) program (2019H1A2A1074096, J. H. K.) of the National Research Foundation of Korea (NRF), funded by the Ministry of Education. We also gratefully acknowledge support from Korea University and Hyupsung University. Publisher Copyright: © The Royal Society of Chemistry.

PY - 2020/11/21

Y1 - 2020/11/21

N2 - Cancer stem cells (CSCs), also called tumor-initiating cells (TICs), have been studied intensively due to their rapid proliferation, migration, and role in the recurrence of cancer. In general, CSC marker-positive cells [CD133, CD44, CD166, aldehyde dehydrogenase (ALDH), and epithelial cell adhesion molecule (EpCAM)] exhibit a 100-fold increased capacity to initiate cancer. Within a heterogeneous tumor mass, only approximately 0.05-3% of cells are suspected to be CSCs and able to proliferate under hypoxia. Interestingly, CSCs, cancer cells, and normal stem cells share many cytochemical properties, such as inhibition of the redox system for reactive oxygen species (ROS) production and high expression of drug resistance transporters. However, compared to normal stem cells, CSCs develop unique metabolic flexibility, which involves switching between oxidative phosphorylation (OXPHOS) and glycolysis as their main source of energy. Due to the similarities between CSCs and other cancer cells and normal stem cells, limited chemotherapeutic and bio-imaging reagents specific for CSCs have been developed. In this short review, we address the current knowledge regarding CSCs with a focus on designing chemotherapeutic and bio-imaging reagents that target CSCs.

AB - Cancer stem cells (CSCs), also called tumor-initiating cells (TICs), have been studied intensively due to their rapid proliferation, migration, and role in the recurrence of cancer. In general, CSC marker-positive cells [CD133, CD44, CD166, aldehyde dehydrogenase (ALDH), and epithelial cell adhesion molecule (EpCAM)] exhibit a 100-fold increased capacity to initiate cancer. Within a heterogeneous tumor mass, only approximately 0.05-3% of cells are suspected to be CSCs and able to proliferate under hypoxia. Interestingly, CSCs, cancer cells, and normal stem cells share many cytochemical properties, such as inhibition of the redox system for reactive oxygen species (ROS) production and high expression of drug resistance transporters. However, compared to normal stem cells, CSCs develop unique metabolic flexibility, which involves switching between oxidative phosphorylation (OXPHOS) and glycolysis as their main source of energy. Due to the similarities between CSCs and other cancer cells and normal stem cells, limited chemotherapeutic and bio-imaging reagents specific for CSCs have been developed. In this short review, we address the current knowledge regarding CSCs with a focus on designing chemotherapeutic and bio-imaging reagents that target CSCs.

UR - http://www.scopus.com/inward/record.url?scp=85092698632&partnerID=8YFLogxK

U2 - 10.1039/d0cs00379d

DO - 10.1039/d0cs00379d

M3 - Review article

C2 - 32633291

AN - SCOPUS:85092698632

SN - 0306-0012

VL - 49

SP - 7856

EP - 7878

JO - Chemical Society Reviews

JF - Chemical Society Reviews

IS - 22

ER -

Cancer stem cell-targeted bio-imaging and chemotherapeutic perspective

Abstract

Bibliographical note

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this